Abemaciclib for pre/perimenopausal women with HR+, HER2-advanced breast cancer

被引：13
|
作者：
Neven, Patrick
Rugo, Hope S.
Tolaney, Sara M.
Iwata, Hiroji
Toi, Masakazu
Goetz, Matthew P.
Kaufman, Peter A.
Barriga, Susana
Lin, Yong
Sledge, George W.
机构：
[1] Univ Hosp Leuven, Leuven, Belgium
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[5] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan
[6] Mayo Clin, Rochester, MN USA
[7] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
[8] Eli Lilly & Co, Madrid, Spain
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.1002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1002
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S7 - S8
  • [32] MONARCHplus: A phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+/HER2-advanced breast cancer (ABC)
    Jiang, Z.
    Hu, X.
    Zhang, Q.
    Sun, T.
    Yin, Y.
    Li, H.
    Costa, R.
    Yan, M.
    Oppermann, C.
    Tong, Z.
    Liu, Y.
    Zhang, Y.
    Cheng, Y.
    Ouyang, Q.
    Chen, X.
    Liao, N.
    Wu, X.
    Wang, X.
    Han, R.
    Lu, Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 863 - 863
  • [33] Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2-advanced breast cancer
    Goetz, M. P.
    Johnston, S.
    Martin, M.
    Tokunaga, E.
    Park, I. H.
    Huober, J.
    Toi, M.
    Price, G. L.
    Boye, M.
    Li, L.
    Forrester, T.
    Gainford, C.
    Gable, J.
    Carter, G. C.
    Sood, A.
    Dileo, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [34] Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer that had exhibited primary or secondary resistance to prior endocrine therapy
    Foster, C.
    Pivot, X.
    Llombart-Cussac, A.
    Neven, P.
    Lin, Y.
    Kaufman, P. A.
    Sledge, Jr G. W.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 289 - 290
  • [35] Dalpiciclib Extends Progression-Free Survival in HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S9 - S10
  • [36] MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2-advanced breast cancer - Results from the preplanned final PFS analysis
    Goetz, Matthew P.
    Martin, Miguel
    Di Leo, Angelo
    Im, Seock-Ah
    Awada, Ahmad
    Forrester, Tammy
    Frenzel, Martin
    Cox, Joanne
    Barriga, Susana
    Toi, Masakazu
    Iwata, Hiroji
    Johnston, Stephen
    CANCER RESEARCH, 2018, 78 (13)
  • [37] Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2-advanced breast cancer: Analysis of the MONARCH trials
    Rugo, H. S.
    Tolaney, S. M.
    Huober, J.
    Toi, M.
    Andre, V.
    Barriga, S.
    Forrester, T.
    Sledge, G. W.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [38] Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2-advanced or metastatic breast cancer: A systematic review and meta-analysis.
    Altaf, Faryal
    Qureshi, Zaheer
    Jamil, Abdur
    Siddique, Rimsha
    Fatima, Eeshal
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Abemaciclib plus fulvestrant in participants with HR+/HER2-advanced breast cancer: A pooled analysis of the endocrine therapy naive (EN) participants in MONARCH 2
    Luis-Gonzalez Trujillo, J.
    Escobar Gomez, M.
    Sohn, J. H.
    Im, Y-H.
    Wang, H-C.
    Cussac, A. Llombart
    Zhang, W.
    Haddad, N.
    Wasserstrom, H.
    van Hal, G.
    Sledge, G. W., Jr.
    ANNALS OF ONCOLOGY, 2021, 32 : S464 - S465
  • [40] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
12345